Lack of extrapyramidal side effects predicts quality of life in outpatients treated with clozapine or with typical antipsychotics

References 

1. Awad AG, Hogan TP. Subjective response to neuroleptics and quality of life: implications for treatment outcome. Acta Psychiatrica Scandinavica. 1994;89:27–32
   • CrossRef
2. Berg D, Jabs B, Merschdorf U, Beckmann H, Becker G. Echogenicity of substantia nigra determined by transcranial ultrasound correlates with severity of parkinsonian symptoms induced by neuroleptic therapy. Biological Psychiatry. 2001;50:463–467
   • Abstract
   • Full Text
   • Full-Text PDF (105 KB)
   • CrossRef
3. Cramer J, Rosenheck R, Xu W, Henderson W, Thomas J, Charney D Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia. Detecting improvement in quality of life and symptomatology in schizophrenia. Schizophrenia Bulletin. 2001;27:227–234
   • MEDLINE
   • CrossRef
4. Geddes J, Freemantle N, Harrison P, Bebbington P. Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. British Medical Journal. 2000;321:1371–1376
5. Heinrichs DW, Hanlon TE, Carpenter WT. The Quality-of-Life Scale: an instrument for rating the schizophrenic deficit syndrome. Schizophrenia Bulletin. 1984;10:388–398
   • MEDLINE
6. Leucht S, Pitschel-Walz G, Abraham D, Kissling W. Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone and sertindole compared to conventional antipsychotic and placebo. A meta-analysis of controlled trials. Schizophrenia Research. 1999;35:51–68
   • Abstract
   • Full Text
   • Full-Text PDF (311 KB)
   • CrossRef
7. Modestin J, Stephan PL, Erni T, Umari T. Prevalence of extrapyramidal syndromes in psychiatric inpatients and the relationship of clozapine treatment to tardive dyskinesia. Schizophrenia Research. 2000;42:223–230
   • Abstract
   • Full Text
   • Full-Text PDF (84 KB)
   • CrossRef
8. Simpson GM, Josiassen RC, Stanilla JK, de Leon J, Nair C, Abraham G, et al. Double-blind study of clozapine dose response in chronic schizophrenia. American Journal of Psychiatry. 1999;156:1744–1750
9. Smith RC, Kadewari RP, Rosenberger JR, Bhattacharyya A. Nonresponding schizophrenia: differentiation by neurological soft signs and neuropsychological tests. Schizophrenia Bulletin. 1999;25:813–825
   • MEDLINE
   • CrossRef
10. Strejilevich S, Palatnik A, Avila R, Bustin J, Cassone J, Figueroa S, et al. Do resistant schizophrenic patients with clozapine improve more than non-resistant patients with typical antipsychotics?. European Psychiatry. 2004;19(Suppl. 1):174S
11. Tauscher J, Kapur S. Choosing the right dose of antipsychotics in schizophrenia: lessons from neuroimaging studies. CNS Drugs. 2001;15:671–678
    • MEDLINE
    • CrossRef
12. Wahlbeck K, Cheine M, Essali A, Adams C. Evidence of clozapine's effectiveness in schizophrenia: a systematic review and meta-analysis of randomized trials. American Journal of Psychiatry. 1999;156:990–999
13. Wolff AL, O'Driscoll GA. Motor deficits and schizophrenia: the evidence from neuroleptic-naive patients and populations at risk. Journal of Psychiatry and Neuroscience. 1999;24:304–314